Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users

Journal of Addiction Medicine

Volumn 5, Issue 3, 2011, Pages 175-180

  Bazazi, Alexander R ^a,b   Yokell, Michael ^a   Fu, Jeannia J ^a   Rich, Josiah D ^a,c   Zaller, Nickolas D ^a,c  

^a MIRIAM HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Buprenorphine; Buprenorphine naloxone; Diversion; Injection drug use; Opiate dependence

Indexed keywords

BENZODIAZEPINE; BUPRENORPHINE; COCAINE; DIAMORPHINE; ILLICIT DRUG; METHADONE; NALOXONE; OPIATE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST; DRUG COST; DRUG MISUSE; DRUG USE; FEMALE; HEALTH CARE ACCESS; HUMAN; INJECTING OPIOID USER; MAJOR CLINICAL STUDY; MALE; METHADONE TREATMENT; MOTIVATION; NONINJECTING OPIOID USER; OPIATE ADDICTION; PATIENT ATTITUDE; PHYSICIAN; SELF MEDICATION; SELF REPORT; URBAN AREA; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; AGED; ATTITUDE TO HEALTH; BUPRENORPHINE; COMORBIDITY; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; NALOXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; RHODE ISLAND; STREET DRUGS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE WITHDRAWAL SYNDROME; URBAN POPULATION; YOUNG ADULT;

EID: 79954515756     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e3182034e31     Document Type: Article

References (25)

1. Barnett Aitken CK, Higgs PG, Hellard ME. Buprenorphine injection in Melbourne, Australia-an update. Drug Alcohol Rev 2008;27(2):197-199.
2. Alho H, Sinclair D, Vuori E, Holopainen A. Abuse liability of buprenorphinenaloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007;88(1):75-78. (Pubitemid 46400304)
3. Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009;35(2):68-72.
4. Cicero TJ, Inciardi JA. Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N Engl J Med 2005;353(17):1863- 1865. (Pubitemid 41549906)
5. Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag 2007;3(6):302-308. (Pubitemid 351166541)
6. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess (Winchester, Engl) 2007;11(9):1-171.
7. Degenhardt L, Larance BK, Bell JR, et al. Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist-antagonist formulation. Med J Aust 2009a;191(3): 161-165.
8. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009b;105(1/2):9-15.
9. Hakansson A, Medvedeo A, Andersson M, Berglund M. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden: purpose of misuse and route of administration. Eur Addict Res 2007;13(4): 207-215. (Pubitemid 47414338)
10. JBS International, Maxwell JC. Diversion and abuse of buprenorphine: a brief assessment of emerging indicators. Report Submitted to Substance Abuse and Mental Health Services Administration, 2006:70.
11. Johnson RE, Jaffe JH, Fudala PJ.Acontrolled trial of buprenorphine treatment for opioid dependence. JAMA 1992;267(20):2750-2755.
12. Kakko J, . Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 2003;361(9358):662-668. (Pubitemid 36246548)
13. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev (Online) 2008;(2):CD002207.
14. Megarbane B, Buisine A, Jacobs F, et al. Prospective comparative assessment of buprenorphine overdose with heroin and methadone: clinical characteristics and response to antidotal treatment. J Subst Abuse Treat 2010;38(4):403-407.
15. Mitchell GS, Kelly SM, Brown BS, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict 2009;18(5):346-355.
16. Monte A, Mandell T, Wilford B, Tennyson J, Boyer E. Diversion of buprenorphine/ naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis 2009;28(3):226-231.
17. Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti JP. Injectingmisuse of buprenorphine among French drug users. Addiction 2001;96(2):267-272. (Pubitemid 32154488)
18. Peterson JA, Schwartz RP, Mitchell SG, et al. Why don't out-of-treatment individuals enter methadone treatment programmes? Int J Drug Policy 2010;21(1):36-42.
19. Reynaud M, Petit G, Potard D, Courty P. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998;93(9):1385-1392. (Pubitemid 28430045)
20. Robinson GM, Dukes PD, Robinson BJ, Cooke RR, Mahoney GN. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug Alcohol Depend 1993;33(1):81-86. (Pubitemid 23219912)
21. Schuman-Olivier Z, Albanese M, Nelson SE, et al. Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat 2010;39(1)41-50
22. Schwartz RP, Kelly SM, O'Grady KE, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict/Am Acad Psychiatrists Alcohol Addict 2008;17(5):396-401.
23. Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003-2005. J Addict Dis 2007;26(3):107-111. (Pubitemid 47367833)
24. Stancliff S, Myers JE, Steiner S, Drucker E. Beliefs about methadone in an inner-city methadone clinic. J Urban Health: Bull N Y Acad Med 2002;79(4):571-578. (Pubitemid 36076530)
25. Zaller ND, Bazazi AR, Velazquez L, Rich JD. Attitudes toward methadone among out-of-treatment minority injection drug users: implications for health disparities. Int J Environ Res Public Health 2009;6(2): 787-797.